A recent study on CLDN6-targeted CAR-NK cells found that combining them with anti-PD-L1 antibodies synergistically boosted anti-tumor efficacy, highlighting the potential of pairing CAR-NK cells with PD-1/PD-L1 inhibitors for cancer therapy (80). Here, CD274 is linked to neoplasm.